{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T21:14:35Z","timestamp":1788556475297,"version":"build-2803163510"},"reference-count":17,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.cllc.2023.12.010","type":"journal-article","created":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T09:28:25Z","timestamp":1704533305000},"page":"274-279","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["STAR-121: A Phase III Randomized Study of Domvanalimab and Zimberelimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Untreated Metastatic Non\u2013Small Cell Lung Cancer With No Actionable Gene Alterations"],"prefix":"10.1016","volume":"25","author":[{"given":"Delvys","family":"Rodriguez-Abreu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim","family":"Bosch-Barrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jhanelle E.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung-Ju","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinwei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trever","family":"Todd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jongseok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Reck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.cllc.2023.12.010_bib0001","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","article-title":"Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2023.12.010_bib0002","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for non-small cell lung cancer V.5.2023. \u00a9 National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed November 19, 2023."},{"issue":"1","key":"10.1016\/j.cllc.2023.12.010_bib0003","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1038\/s41598-021-81666-x","article-title":"Clinical pattern of failure after a durable response to immune checkpoint inhibitors in non-small cell lung cancer patients","volume":"11","author":"Heo","year":"2021","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.cllc.2023.12.010_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2022.02.005","article-title":"Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses","volume":"55","author":"Banta","year":"2022","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.cllc.2023.12.010_bib0005","first-page":"1","article-title":"Co-inhibition of TIGIT and PD-1\/PD-L1 in cancer immunotherapy: mechanisms and clinical trials","volume":"22","author":"Chu","year":"2023","journal-title":"Mol Cancer"},{"issue":"6","key":"10.1016\/j.cllc.2023.12.010_bib0006","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(22)00226-1","article-title":"Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study","volume":"23","author":"Cho","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2023.12.010_bib0007","series-title":"Presented at: Society for Immunotherapy of Cancer","article-title":"Characterization of AB154, a humanized, non-depleting \u03b1-TIGIT antibody undergoing clinical evaluation in subjects with advanced solid tumors","author":"Anderson","year":"2019"},{"issue":"suppl 2","key":"10.1016\/j.cllc.2023.12.010_bib0008","doi-asserted-by":"crossref","first-page":"A124","DOI":"10.1158\/2326-6074.CRICIMTEATIAACR18-A124","article-title":"Abstract A124: preclinical characterization of AB154, a fully humanized anti-TIGIT antibody, for use in combination therapies","volume":"7","author":"Anderson","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"suppl 13","key":"10.1016\/j.cllc.2023.12.010_bib0009","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1158\/1538-7445.AM2019-1557","article-title":"Characterization of AB154, a humanized anti-TIGIT antibody, for use in combination studies","volume":"79","author":"Anderson","year":"2019","journal-title":"Cancer Res"},{"issue":"36","key":"10.1016\/j.cllc.2023.12.010_sbref0010","article-title":"ARC-7: randomized phase 2 study of domvanalimab+ zimberelimab\u00b1etrumadenant versus zimberelimab in first-line, metastatic, PD-L1-high non-small cell lung cancer (NSCLC)","volume":"40","author":"Johnson","year":"2022","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.cllc.2023.12.010_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0345-9","article-title":"Boosting therapeutic potency of antibodies by taming Fc domain functions","volume":"51","author":"Kang","year":"2019","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.cllc.2023.12.010_bib0012","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejca.2021.07.021","article-title":"Efficacy and safety of GLS-010 (zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: a multicenter, single-arm, phase II study","volume":"164","author":"Lin","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cllc.2023.12.010_bib0013","doi-asserted-by":"crossref","first-page":"S1506","DOI":"10.1016\/j.annonc.2022.10.216","article-title":"180O Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, open-label, single-arm, phase II study","volume":"33","author":"Wu","year":"2022","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.cllc.2023.12.010_bib0014","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/19466315.2013.807748","article-title":"Multiple testing in group sequential trials using graphical approaches","volume":"5","author":"Maurer","year":"2013","journal-title":"Stat Biopharm Res"},{"issue":"16","key":"10.1016\/j.cllc.2023.12.010_bib0015","volume":"41","author":"Rodriguez-Abreu","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2023.12.010_bib0016","article-title":"Chemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitors","volume":"12","author":"Zhang","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.cllc.2023.12.010_bib0017","series-title":"Presented at: American Society of Clinical Oncology","article-title":"ARC-10: a phase 3 study to evaluate zimberelimab+ domvanalimab versus pembrolizumab in front-line, PD-L1-high, locally advanced or metastatic non\u2013small-cell lung cancer","author":"Chouaid","year":"2023"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152573042300267X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152573042300267X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T12:59:26Z","timestamp":1728910766000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152573042300267X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S152573042300267X"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2023.12.010","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"STAR-121: A Phase III Randomized Study of Domvanalimab and Zimberelimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Untreated Metastatic Non\u2013Small Cell Lung Cancer With No Actionable Gene Alterations","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2023.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}